Regeneron Pharmaceuticals (REGN) FY2012 results: revenue $1.4 billion, up 209.2% on the year
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $1.4 billion for fiscal 2012, the year ended 31 December 2012, up 209.2% on the year before. Net income was $750 million, and diluted earnings per share $6.75. The figures are the company's own, from the 10-K it filed with the SEC on 15 February 2013.
Revenue
$1.4 billion
+209.2% on the year
FY2008FY2012
Operating margin
33.2%
-46.0% a year earlier
FY2008FY2012
Net income
$750 million
FY2008FY2012
Diluted EPS
$6.75
FY2008FY2012
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Revenue
1,378
446
459
+209.2%
Cost of revenue
83.9
4.2
2.1
+1,890.7%
Gross profit
1,295
442
457
+193.1%
Gross margin
93.9%
99.1%
99.5%
Research and development
626
530
489
+18.1%
Selling, general and administrative
211
117
65.2
+79.7%
Operating income
458
-205
-97.5
Operating margin
33.2%
-46.0%
-21.2%
Interest expense
45.3
21.3
9.1
+112.9%
Pre-tax income
414
-223
-104
Income tax
-336
-1.1
0.0
Effective tax rate
-81.0%
n/a
n/a
Net income
750
-222
-104
Net margin
54.4%
-49.7%
-22.8%
Diluted EPS
$6.75
-$2.45
-$1.26
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Operating cash flow
-74.6
-142
99.2
Capital expenditure
49.3
57.2
99.7
-13.8%
Free cash flow
-124
-199
-0.5
Free cash flow margin
-9.0%
-44.6%
-0.1%
Cash from investing
-81.1
128
-437
Cash from financing
-97.6
384
243
Depreciation and amortisation
36.9
31.1
19.7
+18.8%
Share-based compensation
94.2
56.1
39.9
+67.9%
Diluted shares, weighted
115m
91m
83m
+27.3%
Shares outstanding at period end
n/a
91m
87m
Balance sheet
$ million
FY2012
FY2011
FY2010
On the year
Last 8 years
Shareholders' equity
1,257
486
528
+158.7%
Debt
297
275
0.0
+7.8%
Other liabilities
527
563
562
-6.3%
Total liabilities and equity
2,080
1,324
1,089
+57.2%
Fixed assets
380
368
347
+3.3%
Investments
349
319
507
+9.3%
Cash and equivalents
230
484
113
-52.4%
Receivables
593
28.3
2.3
+1,999.6%
Inventory
28.6
16.6
n/a
+72.4%
Other assets
499
108
120
+362.7%
Total assets
2,080
1,324
1,089
+57.2%
10-K for the year ended 31 December 2012, filed 15 February 2013: the filing.